July 26, 2022Open Access

T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities

Key Points

Key points are not available for this paper at this time.

Abstract

Targeting peptide-MHC complexes, conditional TCE technologies, and concepts enhancing TCE-activated T cells are paving the way towards overcoming challenges associated with solid tumor therapy.

Read Full Paperexternally

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper

Cite This Study

Baeuerle et al. (Tue,) studied this question.

synapsesocial.com/papers/69dc6865ac480df60a133342 https://doi.org/https://doi.org/10.1097/cco.0000000000000869

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Cytokine Storm2020 · 3,178 citations
2Opportunities and challenges for TCR mimic antibodies in cancer therapy2016 · 60 citations
3Updated results from a phase 1 study of AMG 757, a half-life extended bispecific T-cell engager (BiTE) immuno-oncology therapy against delta-like ligand 3 (DLL3), in small cell lung cancer (SCLC).2021 · 49 citations
4IL-2: The First Effective Immunotherapy for Human Cancer2014 · 1,289 citations
5Exploiting the curative potential of adoptive T‐cell therapy for cancer2013 · 472 citations

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper